What Receptor Expression Predicts
ERRα and ERRγ are highly expressed in:
- Skeletal muscle
- Heart
- Liver
- Kidney
- Brown adipose tissue
- Brain (lower levels, but present)
(Tripathi et al., review 2014, PMID 25222219; Schreiber et al., PNAS 2004, PMID 15087503.)
This expression pattern tells researchers where biological effects — beneficial or adverse — are most likely to register. The published mouse data document positive metabolic, cardiac, and hepatic effects in disease models. Whether the same receptor activation produces neutral, beneficial, or adverse effects in healthy human tissue at chronic exposure is the question that has not been studied.
Cardiac Tissue: The Watching-Brief Question
Pan-ERR agonism in cardiac tissue is the single most-discussed theoretical concern. Two reasons:
- ERRα and ERRγ are highly expressed in cardiomyocytes and regulate cardiac fatty acid metabolism.
- Some classes of metabolic agents drive maladaptive cardiac remodeling at chronic exposure.
The Xu 2023 Circulation paper is the relevant data. In mouse pressure-overload heart failure, SLU-PP-332 improved ejection fraction, reduced fibrosis, and did not induce pathological hypertrophy. ERRγ was the main cardioprotective mediator. That is a positive preclinical signal in a disease model.
What it doesn't establish: cardiac safety in normal human hearts at chronic exposure. The mouse trial ran 28 days. Pharmacological ERR pan-agonism for 6, 12, or 24 months has not been studied.
Community self-reports of cardiac symptoms on SLU-PP-332 are sparse. The few reports describe occasional palpitations or warmth after IP-equivalent dosing, with no published mechanism for those reports. None of this is clinical-grade adverse-event data.
Liver: Theoretical Risk, Preclinical Benefit
ERRα is highly expressed in liver and regulates fatty acid oxidation, oxidative phosphorylation, and gluconeogenesis genes. Pharmacological ERR agonism in hepatic tissue is a touch point that researchers monitor.
The published preclinical record is positive: the Billon 2023 metabolic syndrome study reported improved liver markers alongside reduced hepatic fat in DIO mice. No transaminase elevation was reported at the dose tested. Lower liver fat is a predictable consequence of increased fatty acid oxidation.
That is preclinical, in a disease model. Whether chronic ERR pan-agonism in healthy human liver produces similar positive effects, or whether it eventually drives unintended changes in hepatic metabolism, is unstudied.
For research-context bloodwork tracking — including liver enzymes — see the SLU-PP-332 Bloodwork & Biomarkers guide.
Kidney
ERR receptors are expressed in renal tissue, particularly the proximal tubules where they regulate energy metabolism. No mouse study reported renal toxicity at the doses tested, but no kidney-specific stress test (sustained dehydration, contrast loading, etc.) has been run. Conservative community references include creatinine and a basic metabolic panel in pre- and mid-cycle bloodwork.
Community self-reports on SLU-PP-332 are anecdotal, route-dependent, and split.
Injectable SLU-PP-332 (lyophilized vials, reconstituted SC). Most-reported effects on AnabolicMinds and Reddit cluster around:
| Reported effect |
Frequency in community reports |
Notes |
| Mild injection-site reaction |
Common |
Consistent with subcutaneous lipophilic compound |
| Warmth or flushing after dosing |
Occasional |
Reported within 30–90 minutes of injection |
| Sleep disturbance at higher doses |
Occasional |
Mechanism unclear; ERR brain expression is low but present |
| Subjective endurance gains |
Common |
Consistent with mouse data on type IIa fiber shift |
| No effect at all |
Less common |
Usually associated with low community doses or oral cap users incorrectly grouped here |
| Cardiac symptoms (palpitations) |
Rare |
Sparse reports; no published mechanism |
Oral capsules and tablets. Most-reported pattern: no effect of any kind. Consistent with the Billon 2025 paper (PMID 41421047) describing the parent compound as lacking oral bioavailability — if the molecule is not absorbing systemically, the user is taking effective placebo. Community reports of "felt nothing on oral caps" outnumber reports of effect.
Sublingual products. Black Lion Research markets a sublingual SLU-PP-332. Community reports of effect are sparse and unverified by published pharmacokinetic data.
What Has Not Been Studied in Humans
The list is long enough to anchor the safety conversation:
- Phase 1 single-ascending-dose tolerability
- Phase 1 multi-ascending-dose pharmacokinetics
- Drug interaction studies (CYP enzyme effects, transporter interactions)
- Reproductive toxicity
- Carcinogenicity (lifetime rodent studies — none published)
- Long-term cardiac monitoring under chronic dosing
- Effects in any clinical population (T2D, MASH, heart failure, frailty)
- Effects in healthy aging populations
Cardarine (GW-501516) is the comparison most often raised in this context. Cardarine has long-term rodent carcinogenicity data; SLU-PP-332 does not. Absence of carcinogenicity data is not evidence of safety — it means the studies have not been performed.
Theoretical Long-Tail Concerns
These are receptor-biology-driven questions, not documented adverse events:
Mitochondrial overload. ERR pan-agonism drives mitochondrial biogenesis. Whether chronic stimulation produces excess mitochondrial mass that becomes metabolically liable is unstudied in humans.
Off-target ERR signaling. ERRs interact with PGC-1α and other coregulators across many tissue contexts. Whether long-term pharmacological activation produces unintended transcriptional adaptations is unstudied.
Reproductive system. ERRβ and ERRγ are expressed in reproductive tissues. No reproductive toxicity data exist for SLU-PP-332.
Immune effects. No documented immune effects in published studies; ERR receptors are expressed in some immune cell types.
Drug Interactions
Unstudied. The Burris lab characterization work focused on receptor binding, transcriptional outputs, and in vivo phenotypes — not metabolism by CYP enzymes or interactions with common medications. Anyone considering combining SLU-PP-332 with prescription compounds should treat the interaction profile as unknown.
Contraindications (Inferred, Not Established)
There is no formally established contraindication list because no clinical trial has run. Theoretical contraindications based on receptor biology and the absence of safety data:
- Pregnancy or breastfeeding (no reproductive toxicity data)
- Active cardiac disease (despite the positive Xu 2023 finding, that was in a controlled disease model)
- Active liver disease (no clinical data)
- Active malignancy (no carcinogenicity data; receptor activation in cancer cell biology is incompletely characterized)
- Unstudied combinations with prescription metabolic drugs
These are conservative defaults a researcher might apply, not validated clinical contraindications.
Severity Tiers — A Researcher's Decision Framework
Community references describe a rough severity framework for self-experimentation:
Discontinue immediately:
- Unexplained chest pain, palpitations, or shortness of breath
- Acute jaundice or dark urine
- Severe persistent headache or visual changes
Pause and evaluate:
- New persistent fatigue lasting more than a week
- Sleep disruption that doesn't normalize after 7–10 days
- Unexpected lab changes (transaminases, glucose, lipids)
Continue with monitoring:
- Mild injection-site reaction
- Brief warmth or flushing after dosing
- Subjective changes in exercise tolerance (positive direction)
This framework comes from community self-organization, not from any published clinical guidance. Anyone making decisions in this category should be working with a licensed physician.
